menu ☰
menu ˟

ODAC discusses necitumumab for squamous NSCLC but takes no action

09 Jul 2015
An FDA advisory committee today generally expressed support for the approval of necitumumab for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer.However, the Oncologic Drugs Advisory Commi...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.